Journal article · 2022 · Open access

Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study

Yeo‐Jin Song, Soo‐Kyung Cho, Seung‐Hun You, Jeongyeon Kim, Hyoungyoung Kim, Sun‐Young Jung, Yoon‐Kyoung Sung

RMD Open, 8(2), e002614 · Published 1 December 2022 · DOI 10.1136/rmdopen-2022-002614

Open PDFView at the publisherCite this paper

In brief

“Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study” is a 2022 journal article by Yeo‐Jin Song and 6 co-authors, published in RMD Open. OpenAlex counts 14 citations as of 19 November 2026, which puts it in the top 7% of works published in 2022 by citations. It is open access under a CC BY-NC licence: the full text is free to read at RMD Open.

Citations
14
Most cited in
2025 (6)
Field-weighted impact
1.61
References
36
Authors
7

Abstract

OBJECTIVE: To determine the risk of malignancy in Korean patients with rheumatoid arthritis (RA) receiving Janus kinase inhibitors (JAKis) compared with tumour necrosis factor inhibitors (TNFis). METHODS: A retrospective cohort of patients with RA initiating their first JAKi or TNFi was established using the Korean National Health Insurance database between 2015 and 2019. They were followed up from treatment initiation to the occurrence of malignancy, drug discontinuation, death or until December 2019. Baseline features of the patients were balanced through inverse probability of treatment weighting (IPTW) using a propensity score. A Cox proportional hazard model was established to estimate the HR for malignancy risk in JAKi users compared with TNFi users. RESULTS: A total of 4929 patients (1064 JAKi-treated and 3865 TNFi-treated patients) were included, and the observation periods were 1288.6 person-years (PYs) for JAKi users and 6823.8 PYs for TNFi users. The incidence rates of overall malignancy were 0.54 per 100 PYs (95% CI 0.26 to 1.14) in JAKi users and 0.85 per 100 PYs (95% CI 0.66 to 1.10) in TNFi users. In IPTW analysis with a balanced sample (4101 JAKi-treated and 5131 TNFi-treated patients), HR was 0.83 (95% CI 0.55 to 1.27) for overall malignancy: 0.77 (95% CI 0.50 to 1.19) for solid malignancy and 2.86 (95% CI 0.41 to 20.00) for haematological malignancy. CONCLUSION: Malignancy risk in Korean patients with RA was not increased with JAKi use compared with TNFi use.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Song, Y., Cho, S., You, S., Kim, J., Kim, H., Jung, S., & Sung, Y. (2022). Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study. RMD Open, 8(2), e002614. https://doi.org/10.1136/rmdopen-2022-002614

MLA 9

Song, Yeo‐Jin, et al. “Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study.” RMD Open, vol. 8, no. 2, 2022, p. e002614. https://doi.org/10.1136/rmdopen-2022-002614.

Chicago

Song, Yeo‐Jin, Soo‐Kyung Cho, Seung‐Hun You, Jeongyeon Kim, Hyoungyoung Kim, Sun‐Young Jung, and Yoon‐Kyoung Sung. 2022. “Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study.” RMD Open 8 (2): e002614. https://doi.org/10.1136/rmdopen-2022-002614.

Harvard

Song, Y. et al. (2022) ‘Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study’, RMD Open, 8(2), p. e002614. doi:10.1136/rmdopen-2022-002614.

IEEE

Y. Song et al., “Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study,” RMD Open, vol. 8, no. 2, p. e002614, 2022, doi: 10.1136/rmdopen-2022-002614.

BibTeX

@article{song2022association,
  title     = {{Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study}},
  author    = {Song, Yeo‐Jin and Cho, Soo‐Kyung and You, Seung‐Hun and Kim, Jeongyeon and Kim, Hyoungyoung and Jung, Sun‐Young and Sung, Yoon‐Kyoung},
  journal   = {RMD Open},
  year      = {2022},
  volume    = {8},
  number    = {2},
  pages     = {e002614},
  doi       = {10.1136/rmdopen-2022-002614},
  url       = {https://doi.org/10.1136/rmdopen-2022-002614}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202322
202433
202566
202633

Its field-weighted citation impact is 1.61: it has been cited 1.61 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • JAK inhibitors
  • tumor necrosis factor inhibitors
  • cancer risk
  • solid tumors
  • hematologic malignancies
  • drug safety
  • Korean patients

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Song, Y., Cho, S., You, S., Kim, J., Kim, H., Jung, S., & Sung, Y. (2022). Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study. RMD Open, 8(2), e002614. https://doi.org/10.1136/rmdopen-2022-002614

How many times has this paper been cited?

14 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at RMD Open: sign in and open the PDF from this page.

Who wrote this paper?

Yeo‐Jin Song, Soo‐Kyung Cho, Seung‐Hun You, Jeongyeon Kim, Hyoungyoung Kim, Sun‐Young Jung, Yoon‐Kyoung Sung.

What is the DOI of this paper?

10.1136/rmdopen-2022-002614, permanently at https://doi.org/10.1136/rmdopen-2022-002614. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.